Wendell Valdecantos, MD, Sanofi, Cambridge, USA
Articles
OX40-Ligand: A Conductor of the Atopic Dermatitis Inflammatory Symphony?
April W. Armstrong, MD, MPH, Professor and Chief of Dermatology, University of California, Los Angeles;Kassim Rahawi, PharmD, Sanofi, Cambridge, USA;Wendell Valdecantos, MD, Sanofi, Cambridge, USA;Stella Kyaw-Soe, PharmD, MBA, Sanofi, Cambridge, USA
October 22nd 2024Given the complexity of the underlying inflammation in patients with AD, an increased understanding of the OX40L pathway can improve our understanding of AD pathogenesis.
Latest Updated Articles
Published: September 19th 2024 | Updated: September 26th 2024
Final Thoughts: The Importance of Comparative Studies in AD
Published: November 17th 2023 | Updated: May 14th 2025
POLL: What Percent of the Global Population is Estimated to Have Hyperhidrosis?
Published: April 9th 2025 | Updated: May 14th 2025
Test Could Help Identify Patients at Risk for Severe Scleroderma
Published: May 9th 2025 | Updated: May 14th 2025
Artax Presents Phase 2a Results of AX-158 for Plaque Psoriasis
Published: February 28th 2025 | Updated: May 14th 2025
POLL: “Lip Flips” or Lip Filler? Analyzing the Latest Trends in Lip Augmentation
Published: January 23rd 2025 | Updated: May 14th 2025
CT-P39 is Just as Effective as Omalizumab for Chronic Spontaneous Urticaria Treatment
